EnDev Laboratories™, is a full service R&D provider for topical and dermal pharmaceutical development. EnDev has complete formulation and skin biology capabilities including IVRT, extensive analytical resources and stability programs. We can determine mechanisms of action, design proof-of-concept studies, product development de-risking strategies and more, to give you a fact-based foundation for moving forward. EnDev bridges the gap between what is possible and what gets done. EnDev is a division of Ei, A Pharmaceutical SolutionWorks™.
San Diego based, Therapeutics, Inc., The Dermatology CRO was founded in 1997. Approximately 90% of our activities are focused on developing dermatology products. TI is the only dermatology-focused CRO that provides all services required to move a product concept through non-clinical and clinical stages to FDA approval. During the last 5 years: TI managed >11,000 subjects in >90 clinical studies and filed >20 INDs and IDEs in a variety of drug, device and biologic programs.
MedPharm is the world leading specialist pharmaceutical development company, committed to the creation and development of bespoke topical and transdermal formulations for application to the skin, nail, mucous membranes, eye, nose and lung. Alongside developing its own patented dermal drug delivery technologies, MedPharm uses its experience to support customers through regulatory approval previously resulting in biowaivers for generic submissions from regulatory authorities and marketing authorisations for over 60 products in the US and Europe.
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. www.dermtech.com
Tergus is a full-service topical pharmaceutical research, development, testing and manufacturing company. The company is an industry leader for more than 20 years with a state-of-the-art facility in Durham, North Carolina. The company has a long and stellar reputation for delivering quality and results for clients from formulation through manufacturing, which is why people say, “Think Topical. Think Tergus.”
Liquidia precisely engineers uniform drug particles to improve the clinical performance of a wide range of medicines. When formulated for topical administration, PRINT® particles enhance drug penetration, enable delivery and minimize barriers to vehicle development. PRINT® technology can be applied to virtually any composition, size and shape at the micro and nanoscale, overcoming conventional formulation constraints, while reducing manufacturing complexity. Liquidia and its partners have applied PRINT® technology across clinical programs for inhaled, topical, injectable and implantable delivery.
CPL is a leading contract development and manufacturing organization providing product development and commercial manufacturing of non-sterile liquid and semi-solid pharmaceutical and regulated OTC products. Our facilities are registered by FDA and Health Canada and maintain an outstanding record of regulatory compliance. CPL is a reputable contract manufacturer known to provide high quality product with exceptional service. By offering a full-spectrum partnership – from development to commercial production – CPL creates strategic, long-term relationships with our customers.
Novan, Inc. is a pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide platform. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We are rapidly advancing programs in five dermatological conditions with significant unmet medical need.
DPT, a Mylan company, is a leading contract development and manufacturing organization, recognized for its excellence in semi-solid and liquid dosage forms. Backed by a team of approximately 1,000 employees in San Antonio, Texas, DPT has unmatched experience, resources and capacity to efficiently serve your pharmaceutical development and manufacturing needs – no matter the scope. From concept to commercialization, DPT remains committed to exceeding expectations for quality and service.
Bioskin is a leading CRO with unique understanding and capabilities for both early and late phase dermatological clinical trials. Recognized by global companies as a valuable partner in studies for drugs, medical devices, food supplements and advanced cosmetics since 1992, bioskin offers early phase safety and Proof-of-Concept studies, vasoconstrictor assays according to FDA guideline, global Phase II – IV trials for NCEs, new formulations with known actives as well as consulting in the field of dermatology.